Background
==========

Glioma is the most common form of primary brain tumour in adults and generally exhibits a poor prognosis \[[@B1]-[@B3]\]. According to the Chinese Health Statistics Yearbook, the incidence of glioma is approximately five to ten per 100,000 person-years in China. The incidence rate has steadily increased despite significant advances in the diagnosis and treatment of glioma \[[@B4]\]; this increase might be attributed to improvements in diagnostic imaging technology.

The aetiology of this malignancy remains largely unknown. People with inherited diseases such as Li-Fraumeni disease, Neurofibromatosis type 1, and Turcot's disease type 1 exhibit a significantly increased risk of glioma, and consistent with this diversity of predisposing genetic backgrounds, large-scale sequencing of the glioblastoma genome has revealed many genetic alterations \[[@B5],[@B6]\]. Furthermore, there have been many relevant studies focused on the role of polymorphism analysis of candidate genes in glioma risk \[[@B7]-[@B10]\]. Taken together, the evidence thus far provides us with important insight for our understanding of the aetiology of and susceptibility for gliomas.

In recent years, the oxidative stress response has been of particular interest in gliomas, given the high rate of oxygen metabolism in the brain \[[@B11]\]. An excess of oxidative stress, which is triggered by reactive oxygen species (ROS) or reactive nitrogen species (RNS), appears to increase the predisposition for glioma, as an elevated concentration of ROS/RNS can cause DNA damage, repress the activity of cellular enzymes, influence apoptosis and proliferation, and promote tumourigenesis \[[@B12],[@B13]\].

To prevent and mitigate damage caused by ROS/RNS and to maintain redox homeostasis, aerobic organisms have developed efficient defence systems mediated by enzymatic and non-enzymatic antioxidants that can act in a coordinated network \[[@B14]\]. Enzymatic antioxidant defences include superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), paraoxonase (PON), NADPH-quinone reductase (NQO), and nitric oxide synthase (NOS). Intrinsic antioxidant enzymes are vital to the regulation of oxidative stress responses within cells. Genetic variation in these genes might impact the elimination of ROS/RNS and hence increase cancer risk through ROS/RNS effects \[[@B15]\].

In humans, single nucleotide polymorphisms (SNPs) account for a significant proportion of observed genetic mutations and might be associated with cancer risk by altering the expression levels and functions of the affected genes. Numerous studies \[[@B9],[@B16]-[@B24]\] have investigated the association between SNPs in enzymatic antioxidant genes and cancer risk in cancers, including breast cancer, prostate cancer, and a small number of gliomas. To examine whether genetic variation in antioxidant genes is linked with glioma susceptibility, we analysed a set of SNPs and assessed their association with the risk of glioma.

Materials and methods
=====================

Study design and population
---------------------------

The study population consisted of a consecutive series of glioma patients admitted at two centres, specifically, the Department of Neurosurgery of Jiangsu Province Hospital (the First Affiliated Hospital of Nanjing Medical University) and the Chinese Glioma Genome Atlas (Beijing Tiantan Hospital Neurosurgery Centre), from 2005 to 2010. The inclusion criteria for these cases necessitated a newly diagnosed (pathologically or histologically) intracranial glioma (International Classification of Diseases for Oncology, 9th Edition, codes 9380--9481). Histological diagnosis and grading of the tumours were performed in compliance with WHO criteria (World Health Organization, 2007). There were no gender, ethnicity, or cancer stage restrictions on recruitment. After excluding patients with prior cancer history during the baseline visit, a total of 447 glioma patients were invited to participate in the study, of whom 408 (91%) patients consented. Healthy control subjects without a history of cancer were recruited from the health examination clinics of the same two hospitals during the same time period.

The controls matched the case distribution for frequencies of age, sex, ethnicity, and smoking status. Four hundred controls were successfully enrolled. Each participant or proxy was asked to read and sign informed consent agreements in accordance with the requirements of the institutional review board of each participating institution. Following initial patient drop out, 384 glioma patients and 384 cancer-free control patients were included in the final analysis. The study was approved by the Ethics Review Board of Nanjing Medical University.

Data collection
---------------

For both the cases and the controls, information on demographic characteristics, education, occupation, marital status, personal history, family history of cancer in first- and second-degree relatives, and lifestyle habits, including smoking and alcohol consumption, was collected by trained interviewers using a structured questionnaire. Venous blood was collected at each study centre from participants and frozen at −70°C for further molecular analysis.

Selection of genes and polymorphisms
------------------------------------

Through an extensive mining of the databases of the International HapMap Project (HapMap Data Rel 24/phaseII Nov08) and dbSNP, we identified 16 potential functional polymorphisms, which were located within the 5^′^-UTR, 3^′^-UTR, promoter, coding sequence, and splice sites of nine crucial genes involved in oxidative stress response. All of these SNPs exhibit a reported minor allele frequency (MAF) \> 0.05 in the general Han Chinese population (Table [1](#T1){ref-type="table"}).

###### 

Primary information for 16 genotyped SNPs in oxidative pathway genes

  **Genotyped SNPs**         **Location/or Amino acid change**   **MAF for Chinese in database**^**a**^   ***P*value for HWE test**^**b**^   **% Genotyping rate**
  ------------------------- ----------------------------------- ---------------------------------------- ---------------------------------- -----------------------
  *GPX1*: rs1800668 C\>T                 Promoter                                0.078                                 0.706                         99.1
  *CAT*: rs769214 G\>A                   5'region                                0.293                                 0.275                         97.9
  *CAT*: rs7943316 A\>T                  5'region                                0.256                                 0.822                         98.0
  *PON1*: rs854552 T\>C                   3\' UTR                                0.179                                 0.195                         99.1
  *PON1*: rs662 G\>A                    nsSNP/Q192R                              0.430                                 0.424                         97.7
  *NQO1*: rs10517 C\>T                    3\' UTR                                0.381                                 0.397                         97.7
  *NQO1*: rs1800566 T\>C                 nsSNP/S1P                               0.478                                 0.757                         97.5
  *MnSOD*: rs4880 T\>C                  nsSNP/V16A                               0.146                                 0.914                         98.8
  *MnSOD*: rs5746136 G\>A                 3\' UTR                                0.422                                 0.264                         98.7
  *SOD3*: rs2536512 G\>A                nsSNP/T58A                               0.100                                 0.730                         98.6
  *SOD3*: rs2695232 C\>T                  3\' UTR                                0.367                                 0.284                         98.6
  *NOS1*: rs2682826 C\>T                  3\' UTR                                0.256                                 0.163                         98.0
  *NOS1*: rs1047735 T\>C                nsSNP/Q902H                              0.488                                 0.522                         98.4
  *NOS2*: rs2297518 G\>A                nsSNP/L608S                              0.175                                 0.426                         97.2
  *NOS2*: rs10459953 G\>C                Promoter                                0.489                                 0.790                         99.1
  *NOS3*: rs1799983 G\>T                nsSNP/D298E                              0.111                                 0.586                         97.9

Abbreviations: *MAF* minor allele frequency, *HWE* Hardy-Weinberg equilibrium.

^a^Minor allele frequency in the Chinese (CHB, Han Chinese in Beijing, China) population, as reported in dbSNP database.

^b^*P* values were calculated from our control genotype.

Genotyping
----------

Genomic DNA was isolated from peripheral blood leukocytes using phenol-chloroform extraction and proteinase K digestion. Genotyping was performed using the OpenArray platform (Applied Biosystems, Foster City, CA, USA), which employs a chip-based Taq-Man genotyping technology. Genotype calls were made by OpenArray SNP Genotyping Analysis Software version 1.0.3.; laboratory personnel were blinded to the case--control status of each patient sample. For quality control, ten per cent of randomly selected samples were reanalysed with 100% concordant results, and the genotyping success rate for the sixteen SNPs ranged from 97.2% to 99.1%. To further confirm the genotyping results, selected PCR-amplified DNA samples (n = 2, for each genotype) were genotyped a second time using a direct sequencing method, and the results were also consistent.

Statistical analysis
--------------------

All statistical analyses were performed with STATA version 10.0 (Stata Corporation, College Station, TX, USA). The Pearson Chi-squared test was used to assess differences between the cases and the controls with regard to categorical variables, such as gender and smoking status, and to compare observed SNP genotype frequencies with those expected under Hardy-Weinberg equilibrium conditions. Student's *t*-test was used to test for continuous variables, including age and pack-years. Using unconditional logistic regression, we derived odds ratios (ORs) and confidence intervals (CIs) for each polymorphism and associated P-value. Adjusted P-values factored for variables such as age, gender, smoking status, and pack-years were calculated as confounders to exclude potential bias. A test of linear trend with the score was conducted for each SNP using three-level ordinal variable analysis. To correct for multiple comparison testing, we applied the false discovery rate (FDR) \[[@B25]\] method to the *P-*values to reduce the potential for inaccurate findings. In addition to single SNP analysis, we also analysed the association between the total number of unfavourable genotypes and glioma risk. The unfavourable genotypes were combined and categorised according to the tertiles (low, medium, and high risk) of the number of unfavourable genotypes observed in the controls. Using the low-risk group as a reference, we calculated the ORs and 95% CIs for the other subgroups using multivariate logistic regression adjusted for age, gender, smoking status, and pack-years. A two-tailed *P*-value of less than 0.05 was considered statistically significant.

Results
=======

Subject characteristics
-----------------------

The distribution of data on age, gender and smoking status for the cases and controls is shown in Table [2](#T2){ref-type="table"}. The cases and controls were similar in age, gender, and smoking status. We included a total of 384 cases and 384 controls. Table [1](#T1){ref-type="table"} shows the primary information for 16 genotyped SNPs in oxidative pathway genes, including the location, minor allelic frequencies (MAF), and Hardy-Weinberg equilibrium (HWE) tests for the 16 SNPs and their genotyping rates. The genotype distributions in the cases and controls of all SNPs were consistent with Hardy-Weinberg equilibrium.

###### 

Distribution of selected host characteristics by case--control status in Chinese

  **Variables**              **Case (n = 384)**   **Control (n = 384)**   ***P*\***
  ------------------------- -------------------- ----------------------- -----------
  Age, y (mean ± SD)            62.4 ± 10.8            61.5 ± 12.1          0.277
  Gender, no. (%)                                                              
  Male                           222 (57.8)            217 (56.5)           0.715
  Female                         162 (42.2)            167 (43.5)              
  Smoking status, no. (%)                                                      
  Never                          228 (59.4)            218 (56.8)           0.738
  Former                         70 (18.2)              72 (18.7)              
  Current                        86 (22.4)              94 (24.5)              
  Pack-years (mean ± SD)        32.7 ± 25.1            30.3 ± 27.7          0.209
  Tumor grade, no. (%)                                                         
  I                              41 (10.7)                  0                  
  II                             176 (45.8)                 0                  
  III                            86 (22.4)                  0                  
  IV                             81 (21.1)                  0                  

\**P* values were derived from the ***χ***^2^ test for categorical variables (gender and smoking status) and *t* test for continuous variables (age and pack-years).

Main analyses of effects due to individual polymorphisms
--------------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, four SNPs (*SOD2* V16A*, SOD3* T58A*, GPX1* -46 C/T*,* and *NOS1* 3'-UTR) demonstrated a significant association with glioma risk, as determined by the dominant model (variant-containing genotypes versus common homozygote). Compared to *SOD2* 16Val homozygotes, carriers with the *SOD2* 16Ala allele exhibited a more than 1.86-fold increased risk of glioma occurrence (adjusted OR = 1.86; 95% CI = 1.35-2.55), where the risk increased significantly with the increasing number of variant alleles (*P-trend* \< 0.001). Similarly, individuals with the SOD3 58A allele exhibited a significant association with the risk of glioma occurrence compared to the 58T homozygotes (adjusted OR = 1.64; 95% CI = 1.20--2.23; *P-trend* \< 0.001). Furthermore, we observed an increased risk of glioma occurrence associated with the *GPX1* rs1800668 variant (adjusted OR = 1.18; 95% CI = 0.82--1.69). In contrast, we observed a decreased glioma risk associated with the *NOS1* rs2682826 variant (adjusted OR = 0.61; 95% CI = 0.45-0.82; *P-trend* = 0.017).

###### 

Allelic and genotypic frequencies and risks for glioma in Chinese

  **Genotyped SNPs**                                         **MAF**    **Common homozygote (*n*)**   **Heterozygote (*n)***   **Rare homozygote (*n*)**   **Heterozygote and rare Homozygote (*n*)**   ***P*for trend**
  ------------------------------------ ------------------- ----------- ----------------------------- ------------------------ --------------------------- -------------------------------------------- ------------------
  ***GPX1*promoter (rs1800668)**       Case                   0.12                  301                         66                        13                                   79                               
  Control                              0.09                    314                  64                          4                         68                                 0.110                     
  OR (95% CI)**\***                                         Reference        1.05 (0.72-1.53)         **3.30 (1.07-10.24)**        1.18 (0.82-1.69)                                                    
  *CAT* 5'region (rs769214)            Case                   0.28                  198                        146                        32                                  178                               
  Control                              0.29                    192                  146                         36                        182                                0.609                     
  OR (95% CI)**\***                                         Reference        0.93 (0.69- 1.26)          0.83 (0.49- 1.39)          0.91 (0.68- 1.21)                                                   
  *CAT* 5'region (rs7943316)           Case                   0.33                  180                        140                        53                                  193                               
  Control                              0.29                    195                  153                         32                        185                                0.074                     
  OR (95% CI)**\***                                         Reference        1.04 (0.77- 1.41)          1.16 (0.75- 1.79)          1.19 (0.89- 1.58)                                                   
  *PON1* 3\' UTR (rs854552)            Case                   0.22                  237                        120                        23                                  143                               
  Control                              0.23                    231                  126                         24                        150                                0.653                     
  OR (95% CI)**\***                                         Reference        0.96 (0.70- 1.30)          0.96 (0.53- 1.75)          0.96 (0.71- 1.28)                                                   
  *PON1* Q192R (rs662)                 Case                   0.35                  161                        158                        52                                  210                               
  Control                              0.36                    159                  167                         52                        219                                0.833                     
  OR (95% CI)**\***                                         Reference        0.98 (0.72- 1.34)          1.06 (0.68- 1.65)          1.00 (0.75- 1.33)                                                   
  *NQO1* 3\' UTR (rs10517)             Case                   0.39                  142                        170                        60                                  230                               
                                       Control                0.35                  154                        181                        44                                  225                            0.162
                                       OR (95% CI)**\***                         Reference              0.99 (0.73- 1.35)          1.44 (0.92- 2.26)                   1.08 (0.81- 1.45)                        
  *NQO1* S1P (rs1800566)               Case                   0.46                  109                        181                        78                                  259                               
  Control                              0.47                    108                  187                         86                        273                                0.610                     
  OR (95% CI)**\***                                         Reference        1.00 (0.71- 1.39)          0.93 (0.62- 1.40)          0.98 (0.71- 1.34)                                                   
  ***MnSOD*V16A (rs4880)**             Case                   0.22                  241                        107                        31                                  138                               
  Control                              0.12                    293                  81                          6                         87                              **\<0.001**                  
  OR (95% CI)**\***                                         Reference      **1.55 (1.11- 2.16)**      **6.05 (2.48- 14.74)**     **1.86 (1.35- 2.55)**                                                 
  *MnSOD* 3\' UTR (rs5746136)          Case                   0.51                  95                         182                        100                                 282                               
  Control                              0.46                    118                  178                         85                        263                                0.058                     
                                       OR (95% CI)**\***                         Reference              1.17 (0.83- 1.64)          1.34 (0.90- 1.99)                   1.22 (0.89- 1.68)                        
  ***SOD3*T58A (rs2536512)**           Case                   0.25                  235                         96                        44                                  140                               
  Control                              0.11                    283                  73                          25                        98                              **\<0.001**                  
  OR (95% CI)**\***                                         Reference      **1.51 (1.06- 2.14)**      **2.01 (1.20- 3.39)**      **1.64 (1.20- 2.23)**                                                 
  *SOD3* 3\' UTR (rs2695232)           Case                   0.41                  142                        165                        75                                  240                               
  Control                              0.41                    134                  172                         70                        242                                0.922                     
  OR (95% CI)**\***                                         Reference        0.87 (0.63- 1.19)          0.97 (0.65- 1.45)          0.90 (0.67- 1.20)                                                   
  ***NOS1*** 3\' UTR **(rs2682826)**   Case                   0.25                  209                        104                        23                                  127                               
  Control                              0.28                    193                  164                         24                        188                              **0.017**                   
  OR (95% CI)**\***                                         Reference      **0.57 (0.42- 0.79)**        0.87 (0.47- 1.59)        **0.61 (0.45- 0.82)**                                                 
  *NOS1* Q902H (rs1047735)             Case                   0.46                  123                        165                        90                                  255                               
  Control                              0.49                    101                  183                         94                        277                                0.197                     
  OR (95% CI)**\***                                         Reference        0.80 (0.57- 1.11)          0.85 (0.57- 1.25)          0.81 (0.60- 1.11)                                                   
  *NOS2* L608S (rs2297518)             Case                   0.19                  241                        120                         8                                  128                               
  Control                              0.17                    255                  113                         9                         122                                0.584                     
  OR (95% CI)**\***                                         Reference        1.10 (0.80- 1.50)          0.92 (0.35- 2.42)          1.08 (0.80- 1.47)                                                   
  *NOS2* promoter (rs10459953)         Case                   0.40                  140                        178                        64                                  242                               
  Control                              0.44                    122                  184                         73                        257                                0.173                     
  OR (95% CI)**\***                                         Reference        0.88 (0.64- 1.21)          0.80 (0.53- 1.21)          0.86 (0.64- 1.16)                                                   
  *NOS3* D298E (rs1799983)             Case                   0.15                  282                         77                        17                                   94                               
  Control                              0.12                    278                  84                          15                        99                                 0.856                     
  OR (95% CI)**\***                                         Reference        0.91 (0.64- 1.29)          1.12 (0.55- 2.29)          0.94 (0.68- 1.30)                                                   

\*Multivariable adjustment by age, gender (male or female), smoking status (never, former or current), and pack-years.

Data in *boldface* represent *P* \< 0.05.

MAF: Minor Allele frequency.

Combined effects of the unfavourable genotypes
----------------------------------------------

To understand the cumulative effects of these variants on glioma risk, we performed an unfavourable genotype analysis for four SNPs that had significant and borderline significant associations with glioma risk, including rs1800668 (CC), rs4880 (TT), rs2536512 (GG), and rs2682826 (TC+ TT). Compared to the reference group exhibiting no unfavourable genotypes, the OR for the medium risk group with two unfavourable genotypes was 1.86 (95% CI, 1.30-2.76), and the OR was increased to 4.86 (95% CI, 1.33--17.71) for the high-risk group with 3 unfavourable genotypes (Table [4](#T4){ref-type="table"}).

###### 

Joint effects of unfavorable genotypes in case patients and control subjects in Chinese

  **Risk group (no. unfavorable genotypes)**    **Cases**   **Controls**   **OR (95% CI)\***
  -------------------------------------------- ----------- -------------- -------------------
  Reference group^a^ (n = 0)                       147          205            Reference
  Low-risk reference group (n = 1)                 96            83        1.51 (1.05- 2.17)
  Medium-risk group (n = 2)                        108           76        1.86 (1.30-2.67)
  High-risk group ^b^ (n ≥3)                       11            3         4.86 (1.33-17.71)
  *P* for trend                                                                 \<0.001

\*Adjusted for age, gender, smoking status, and pack-years.

^a^Reference group: *GPX1* promoter: CC, *MnSOD* V16A: TT, *SOD3* T58A: GG, and *NOS1* 3\' UTR: CT+TT.

^b^Because the subject number in group '4' was sparse (one control and three patients), the subjects with greater than three unfavourable genotypes were combined as the high-risk group.

Discussion and conclusion
=========================

Emerging evidence from in vitro, animal, and human studies has indicated that ROS/RNS and the activation of redox-sensitive signalling pathways play a crucial role in cancer development \[[@B26]-[@B29]\]. Such antioxidant mechanisms are extremely important, as they represent the direct removal of ROS/RNS, particularly during gliomatous carcinogenesis. To investigate the potential association between SNPs in antioxidant defence genes and the risk of glioma occurrence, we conducted this case--control study. In this study, we observed a statistically significant association between four SNPs (*SOD2* V16A*, SOD3* T58A*, GPX1* -46 C/T*,* and *NOS1* 3'-UTR) of antioxidant genes and the risk of glioma occurrence in a Chinese population. Additionally, three SNPs exhibited statistically significant evidence of differential dose--response associations. To the best of our knowledge, this is the first report of an association study between antioxidant gene SNPs and glioma risk in a Chinese population.

SODs are a ubiquitous family and represent the most important line of antioxidant enzyme defence against ROS, particularly the superoxide anion radicals \[[@B13]\]. SOD enzymes, which catalyse the spontaneous dismutation of the superoxide radical into hydrogen peroxide, are present in all subcellular milieus of the nervous system, including the mitochondrial intermembrane space (SOD1; copper/zinc SOD); the mitochondrial matrix (SOD2; manganese SOD); and the plasma, lymph, and synovial fluids (SOD3; extracellular SOD) \[[@B30]\]. Superoxide dismutase 2 (SOD2) (also known as manganese superoxide dismutase \[MnSOD\]) is an essential defender against mitochondrial superoxide radicals.

SOD2 converts the superoxide anion radical into hydrogen peroxide and oxygen within mitochondria and plays a key role in protecting cells from oxidative damage \[[@B31]\]. In the early stages of carcinogenesis, oxidative stress and relatively low levels of MnSOD result in DNA damage and cell injury \[[@B32]-[@B34]\]. MnSOD plays a critical role in the defence against oxidant-induced injury and apoptosis of rapidly growing cancer cells, and the tumour-suppressive effects of MnSOD have been well established \[[@B12],[@B14],[@B35]\]. Whereas Chung-man et al. \[[@B36]\] and Izutani et al. \[[@B37]\] previously found increased SOD2 levels in cancer cells, other studies have reported elevated MnSOD expression levels in aggressive cancers compared to benign counterparts, and this increased expression has been proposed to enhance metastasis following cancer progression, possibly through increased expression of matrix metalloproteinases (MMP) \[[@B38],[@B39]\], which is one possible mechanism supporting the role of SOD2 in cancer invasiveness and metastatic capacity. The overexpression of SOD2 can also induce increased levels of hydrogen peroxide (H2O2) \[[@B40],[@B41]\]. H2O2 is a major intracellular oxidant and induces DNA damage in glioma cells \[[@B42],[@B43]\]. Although it might be difficult to determine the precise mechanisms that are most relevant to the pathologies of the patients in this study, the identification of these two possible mechanisms is consistent with our results.

To our knowledge, most epidemiological studies have indicated that SOD2 polymorphisms are linked to clinically significant increases in colon, gastric, lung, breast, and prostate cancers \[[@B16]-[@B20]\]. These polymorphisms have also been linked to the development of meningiomas and glioblastomas \[[@B44]\]. Here, our results revealed a statistically significant association between SOD2 rs4880 and the risk of glioma. Rajaraman P et al. \[[@B30]\] showed an increased risk of acoustic neuroma with the SOD2 (Val16Ala) Ala variant, but no significant association between the C genotype and the risk of glioma was observed. The T-to-C nucleotide polymorphism (rs4880), which converts a valine to an alanine in the mitochondrial targeting sequence at position 16 of the protein (Val16Ala), is considered one of the most interesting polymorphisms in the SOD2 gene. The Val-to-Ala transition alters the secondary structure of the protein, resulting in more efficient transport of SOD2 into the mitochondrial matrix. Thus, the C allele can increase the ability of SOD2 to neutralise superoxide radicals compared to the T allele \[[@B45],[@B46]\]. Diffuse invasion into the surrounding brain is a characteristic feature of gliomas, essentially preventing surgical cure, leading to recurrence and representing perhaps the largest obstacle to effective therapy. The invasive nature of glioma cells into the brain parenchyma is intimately linked to the degradation of the extracellular matrix. Activated MMPs are a prerequisite for cancer cell invasion and metastasis. Several lines of evidence have suggested that the overexpression of SOD2 induces a profound increase in the expression of MMP-1 \[[@B47]-[@B49]\]. Because the Ala mutant confers a 40% higher MnSOD activity than the Val wild-type form, the increased levels of SOD2 result in increased risk for more invasive glioma activity by inducing MMPs. Our results are consistent with this function of the SOD2 rs4880 in glioma and warrant further investigation. A recent study has indicated that SOD2 rs4880 might significantly modulate the prognosis of breast cancer patients \[[@B31]\], implicating SOD2 rs4880 as a potential prognostic biomarker in gliomas.

Our results also indicate a role for SOD3 rs2536512 in the risk of glioma and demonstrated that the SOD3 A genotype correlated with a significantly increased risk of glioma occurrence in a Chinese population. SOD3 was first detected in human plasma, lymph, ascites, and cerebrospinal fluids \[[@B50]\]. This SNP (rs2536512) results in a threonine-to-alanine conversion that replaces a polar hydrophilic amino acid with an aliphatic hydrophobic amino acid at position 58 of the SOD3 protein, eliminating a PKC delta phosphorylation motif \[[@B51]\]. Few studies have been performed to examine the association between SOD3 rs699473 and glioma risk or to explore the association between SOD3 rs2536512 and cerebral infarction in women \[[@B52]\]. Our study has demonstrated an association between the human SOD3 gene and the risk of glioma occurrence. Additionally, we observed statistically significant evidence that carriers of the SOD2 and SOD3 variants exhibit increased glioma dose--response relationships compared with homozygous wild-type subjects (P-trend \< 0.001). Confirmation of our findings in alternate populations represents a high priority. The SOD SNP-associated glioma risks observed in our study suggest that the amino acid changes caused by these SNPs might be physiologically significant in the development of cancer.

GPX1 encodes the antioxidant glutathione peroxidase isoform 1 and acts in conjunction with the tripeptide glutathione (GSH), which is present in cells in high (micromolar) concentrations \[[@B53]\]. Accumulating data link altered or abnormal GPX1 expression with the aetiology of cancer \[[@B54]-[@B56]\]. The additional identification of GPX1 polymorphisms, concordant with several other studies, suggests the involvement of GPX1 variants in the aetiology of glioma \[[@B30],[@B57]\]. In these previous studies, the effect sizes occurred at an odds ratio of approximately 1.1; in our study, the rs1800668 SNP in GPX1 was associated with an almost 3.3-fold increased risk when rare homozygotes were compared to common homozygotes. Although the previous studies indicated the same association that was observed in our results, they lacked statistical significance and association. Thus, it is likely that some associations that we have presented here are chance findings. These data only provide evidence that GPX1 rs1800668 contributes to glioma predisposition. Further epidemiologic and functional studies in a larger population are warranted to validate these results.

Nitric oxide (NO), a pleiotropic messenger molecule, is predominantly produced from the precursor L-arginine by neuronal nitric oxide synthase (NOS1) in the central nervous system \[[@B58],[@B59]\]. The possible involvement of NOS1 rs2682826 in vital functions has been suggested by several studies. The rs2682826 SNP is located in the 3^′^-UTR of exon 29 of NOS1 gene. It has been established that the 3^′^-UTR plays a role in the stability and translational efficiency of the mRNA transcript \[[@B60]\]. Additionally, the rs2682826 SNP is proximally located to several miRNA-binding sites within the gene's 3^′^-UTR. Differences in protein translation might occur depending on the presence of the SNP in the mRNA of this gene \[[@B24]\]. Further functional analyses are required to clarify these possibilities.

In this population sample, NOS1 rs2682826 might play a protective role in the development of glioma under the dominant model (adjusted OR = 0.61; 95% CI = 0.45--0.82; *P-trend* = 0.017). Additional evidence substantiating the physiological relevance of the NOS1 rs2682826 polymorphisms was previously revealed by Ibarrola-Villava et al. \[[@B24]\], who found that NOS1 rs2682826 is associated with protective effects in malignant melanoma, accounting for a 40% reduction. If confirmed, the evidence presented in this study here would facilitate the identification of individuals who possess the heterozygote or rare homozygote marker of NOS1 rs2682826. These patients would particularly benefit from glioma treatments.

However, the limitations of our study must be addressed. First, these findings cannot be generalised to other populations because our study was specifically conducted using a Chinese population. Second, the number of cases and controls included in this study was relatively small; thus, further studies with larger sample-sizes are needed.

In conclusion, we have demonstrated that the influence of these genetic variations in the oxidative response has a potential regulatory effect on glioma tumourigenesis, and furthermore, we have identified a trend towards an increasing glioma risk associated with an increasing number of unfavourable genotypes that occur in a dose-dependent manner. To our knowledge, this study provides the first epidemiological evidence that supports an association between oxidative response-related genes and glioma risk in a Chinese population. Further studies are warranted to assess the observed effects using a more comprehensive collection of SNPs in oxidative response genes.

Abbreviations
=============

SOD: Superoxide dismutase; GPx: Glutathione peroxidase; CAT: Catalase; PON: Paraoxonase; NQO: NADPH-quinone reductase; NOS: Nitric oxide synthase; SNP: Single nucleotide polymorphism; MMP: Matrix metalloproteinases; OR: Odds ratio; CI: Confidence interval.

Competing interests
===================

The authors declare that they have no competing interests.

Authors' contributions
======================

PZ and LZ participated in the collection of data and manuscript preparation. PZ and LZ performed the statistical analysis. NL, WY, CK, ZF, YY and TJ collected the samples. PZ and AL participated in the study design and critically revised the manuscript. PZ and TJ participated in the study design and manuscript preparation. All of the authors read and approved the final manuscript.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/12/617/prepub>

Acknowledgements
================

We thank Prof. Aihua Gu and Dr. Guixiang Ji in the School of Public Health of Nanjing Medical University for statistical analysis. This work was supported by the National Natural Science Foundation of China (grant 30901534), the Natural Science Foundation of Jiangsu Province (Proj. no. BK2009444), the Grant for the 135 Key Medical Project of Jiangsu Province (No. XK201117), and the National High Technology Research and Development Program 863 (No. 2012AA02A508).
